Newman Lucy M, Kavanagh Oisín N, Machado Tatiane C
School of Pharmacy, Newcastle University, United Kingdom.
School of Pharmacy, Newcastle University, United Kingdom.
Int J Pharm. 2025 Feb 25;671:125298. doi: 10.1016/j.ijpharm.2025.125298. Epub 2025 Jan 30.
Synchronising both cocrystal dissolution and drug precipitation processes is the key for the development of cocrystal systems with desired dissolution-supersaturation-precipitation (DSP) behaviours. Our findings with ketoconazole (KTZ) - p-aminobenzoic acid (PABA) 1:1 cocrystal show that this can be achieved by generating non-stoichiometric coformer concentrations that allow us to modulate the maximum theoretical cocrystal supersaturation SA (thermodynamic limit) below the drug critical supersaturation σ (kinetic limit). The application of our conceptual graphical approach combined with the two metrics SA and the DSP answer the question of how much additional coformer is needed to target optimal sustained drug supersaturation levels. Modulating SA < σ and DSP > 1 allowed for a stable and sustained KTZ release system with supersaturation levels of 6 by 24 h. Findings provide a direct approach for better early decisions regarding cocrystal dose design and/or coformer concentration to be added to formulations to ultimately fine-tune drug supersaturation by coupling dissolution and precipitation processes.
使共晶体溶解和药物沉淀过程同步进行,是开发具有理想溶解-过饱和-沉淀(DSP)行为的共晶体系统的关键。我们对酮康唑(KTZ)-对氨基苯甲酸(PABA)1:1共晶体的研究结果表明,这可以通过生成非化学计量的共形成剂浓度来实现,该浓度使我们能够将最大理论共晶体过饱和度SA(热力学极限)调节至低于药物临界过饱和度σ(动力学极限)。我们的概念性图形方法与SA和DSP这两个指标相结合,回答了需要多少额外的共形成剂才能达到最佳持续药物过饱和水平的问题。调节SA < σ且DSP > 1可实现稳定且持续的KTZ释放系统,24小时内过饱和水平为6。这些发现为在共晶体剂量设计和/或添加到制剂中的共形成剂浓度方面做出更好的早期决策提供了直接方法,以便最终通过耦合溶解和沉淀过程来微调药物过饱和度。